someone explain biopsy to me like I have not read a paper in years
Slightly embarrassed to be asking this, but: someone explain biopsy to me like I have not read a paper in years. Bought small because the evidence base is early. That is the only defensible position I could construct. The honest evidence position, written out so this board does not drift. Phase 2 data exists in a…
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.
Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.
the weight numbers are secondary to what this is being developed for
Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.
Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.
Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.